PA
BPMC

Perceptive Advisors’s Blueprint Medicines BPMC Stock Holding History

Perceptive Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-664,574
Closed -$61.6M – 145
2020
Q3 		$61.6M Sell
664,574
-24,050
-3% -$1.85M 0.9% 29
2020
Q2 		$53.7M Hold
688,624
– – 0.87% 29
2020
Q1 		$40.3M Buy
688,624
+70,000
+11% +$4.5M 1.05% 21
2019
Q4 		$49.6M Sell
618,624
-264,640
-30% -$19.8M 0.98% 24
2019
Q3 		$64.9M Sell
883,264
-329,467
-27% -$28.5M 1.75% 16
2019
Q2 		$114M Sell
1,212,731
-58,323
-5% -$4.81M 2.63% 11
2019
Q1 		$102M Buy
1,271,054
+413,728
+48% +$30.6M 2.87% 10
2018
Q4 		$43.5M Sell
857,326
-83,821
-9% -$5.09M 1.65% 18
2018
Q3 		$73.5M Sell
941,147
-20,000
-2% -$1.39M 1.96% 12
2018
Q2 		$61M Sell
961,147
-69,287
-7% -$5.51M 1.6% 15
2018
Q1 		$94.5M Sell
1,030,434
-110,000
-10% -$9.48M 2.65% 10
2017
Q4 		$86M Buy
1,140,434
+715,773
+169% +$50.4M 2.85% 7
2017
Q3 		$29.6M Sell
424,661
-20,000
-4% -$1.07M 1.13% 20
2017
Q2 		$22.5M Sell
444,661
-16,981
-4% -$721K 1.13% 24
2017
Q1 		$18.5M Buy
461,642
+187,822
+69% +$6.73M 1.05% 29
2016
Q4 		$7.68M Sell
273,820
-186,204
-40% -$5.61M 0.55% 47
2016
Q3 		$13.7M Sell
460,024
-4,380
-0.9% -$109K 0.88% 27
2016
Q2 		$9.4M Buy
464,404
+60,000
+15% +$1.09M 0.65% 38
2016
Q1 		$7.3M Hold
404,404
– – 0.64% 41
2015
Q4 		$10.7M Hold
404,404
– – 0.79% 33
2015
Q3 		$8.63M Hold
404,404
– – 0.69% 36
2015
Q2 		$10.7M Buy
+404,404
New +$11.5M 0.65% 39

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors's BPMC Position: Q4 2020 in Review

Perceptive Advisors sold out of Blueprint Medicines (BPMC) in Q4 2020, closing a stake of 664,574 shares — an estimated $61.6M sold.

Perceptive Advisors first reported a position in BPMC in Q2 2015 and held it in 22 quarters. The position peaked at $114M in Q2 2019. 279 funds tracked by Wall St. Rank hold BPMC as of Q4 2020.

  • Perceptive Advisors reported no remaining Blueprint Medicines position as of Q4 2020 after selling out during the quarter.
  • Perceptive Advisors sold 664,574 Blueprint Medicines shares in Q4 2020, an estimated $61.6M.
  • Perceptive Advisors first reported a position in Blueprint Medicines in Q2 2015 and held it in 22 quarters.
  • Perceptive Advisors's Blueprint Medicines position peaked at $114M in Q2 2019.
  • 279 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2020.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.